Sanofi's Multaq Use Should Be Restricted, EU Drug Regulator Says

The drug should only be prescribed to patients with a persistent, paroxysmal irregular heartbeat, and then only after alternative treatments have been tried, the London-based agency said today in a statement on its website. The decision will wipe out …
See all stories on this topic »